Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Case Rep
Autori principali: Klein, Klara, Asaad, Shonda, Econs, Michael, Rubin, Janet E
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2018
Soggetti:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/
https://ncbi.nlm.nih.gov/pubmed/29298794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi